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Abstract
Background: Previous observational studies have indicated that green tea (GT) consumption is associated
with reduced mortality from cerebral infarction but not with mortality from cerebral hemorrhage. Therefore,
we hypothesized that GT exerts a direct antiatherosclerotic effect without any effect on hypertension. To
investigate this hypothesis, we focused on adiponectin that seems to be among the several key players in
atherosclerosis.
Objective: The objective of this randomized controlled trial (RCT) was to assess whether the consumption
of catechin-enriched GT affects serum adiponectin levels and cardiovascular disease (CVD) risk factors
among apparently healthy subjects.
Design: A total of 51 individuals participated in the study. Eligible participants were randomly assigned into
GT consumption groups with either high catechin (400 mg/day) or low catechin (100 mg/day). The study
participants were asked to stop GT consumption for 2 weeks (washout period), following which they were
to start drinking the provided GT beverages everyday for 9 weeks. The outcome measures were changes in
the adiponectin levels and CVD risk factors (body weight, body mass index, waist circumference, blood
pressure, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycer-
ide, fasting plasma glucose, as well as aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl
transpeptidase, uric acid, and high-sensitive C-reactive protein).
Results: After intervention for 9 weeks, we found no significant difference between the high- and low catechin
group with respect to changes in the serum adiponectin level: 0.35 mg/ml (95% confidence interval (CI):
1.03, 1.74). Also, no significant difference was observed between the high- and low catechin groups with
respect to changes in any of the measured CVD risk factors.
Conclusion: This RCT showed no significant difference between the high-and low catechin groups with
respect to changes in the serum adiponectin level and any CVD risk factors.
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S
ubstantial evidence from in vitro and animal studies
indicates that green tea (GT) preparations inhibit
cardiovascular disease (CVD) processes (14). In
our previous observational study, we showed that GT
consumption was associated with a significantly lower
risk of mortality due to CVD among middle-aged adults
(5). The study also indicated that GT consumption was
associated with reduced mortality from cerebral infarc-
tion but not with mortality from cerebral hemorrhage.
These associations were consistent with those reported in
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sized that GT exerts a direct antiatherosclerotic effect
not mediated via any effect on hypertension. To investi-
gate this hypothesis, we focused on adiponectin that is
among the several key players that seem to play a direct
role in atherosclerosis. Adiponectin inhibits proliferation
of migrated smooth muscle cells (7), monocyte adhesion
to endothelial cells, and oxidized low-density lipoprotein
(LDL) uptake of macrophages and has been shown to
have direct effects on atherosclerotic lesions (8). In
addition, some human studies suggested that high plasma
adiponectin concentrations are associated with a lower
risk of CVD (912), and observational studies have
indicated an antiatherosclerotic role of adiponectin
(13, 14).
Several animal experiments have indicated that the
intake of GT increases the adiponectin level (1517). To
date, three randomized controlled trials (RCTs) have
examined the association between tea catechin consump-
tion and adiponectin levels in humans, but none reported
a significant increase in adiponectin by GT catechin
consumption (1820). Because these RCTs recruited
patients with diabetes mellitus and obesity, further
evidence among healthy subjects is needed to obtain
some consensus on this issue. We, therefore, designed this
RCT to assess whether consumption of catechin-enriched
GTaffects serum adiponectin levels and CVD risk factors
among apparently healthy subjects.
Subjects and methods
Study participants and intervention program
The study was conducted between June 2007 and
September 2007, and between December 2007 and
February 2008. The persons included in the present study
were those who participated in a weight loss program
at Sendai Health Promotion Center (weight loss program
participants) and the staff of Sendai Health Promotion
Center (weight loss program non-participants) in Japan.
The inclusion criteria for the intervention program
were (1) both sexes and (2) age between 20 and 70 years.
The exclusion criteria were history of diabetes mellitus,
cancer, ischemic heart disease, stroke, or renal disease.
The weight loss program was based on exercise program
(exercise guidance, stretching exercise, and strength
training) and nutritional program (nutritional guidance
and cooking practice). With a mean9SD value of
597mg/ml in adiponectin, a minimum sample size of
50 subjects would be required to detect a difference
(power70%, two-sided a0.05). We asked 60 subjects
to participate in this study and obtained informed
consent from 51 subjects. The study protocol was
reviewed and approved by the Ethics Committee of
Tohoku University Graduate School of Medicine.
We used commercially available catechin-containing
beverages (500 ml). According to the data provided
by the manufacturer, the high-concentration beverage
contained 400 mg catechin and the low-concentration
beverage, 100 mg (Table 1). We purchased the beverages
and then delivered them to the participants’ residences.
Adherence to the study protocol was confirmed by asking
the subjects to return the bottle caps and by reviewing
their consumption records. Eligible participants were
stratified by sex (men or women) and the weight loss
program (participation or non-participation), and rando-
mization was conducted by permuted block method using
a four-person block. A total of 51 participants were
randomly assigned by an epidemiologist (NN) to either
the high catechin group (N25) or the low catechin
group (N26) (Fig. 1). The study participants were
asked to stop GT consumption for 2 weeks (washout
period), following which they were to start drinking the
provided GT beverages everyday for 9 weeks. During
the intervention period, the participants were asked
not to drink any other catechin-containing beverage;
other beverages were allowed. The participants and
research assistants were blinded to the group allocation.
Both the catechin-enriched beverages had similar taste
and appearance. At the end of the study, the blinding
of the participants was evaluated. (Register No:
UMIN000000742).
Outcome measures
The outcome measures were changes in the adiponectin
levels and CVD risk factors: body weight, body mass
index (BMI), waist circumference, blood pressure (BP),
and levels of total cholesterol (TC), LDL cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C),
triglyceride (TG), fasting plasma glucose, as well as
aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), gamma-glutamyl transpeptidase (g-GTP),
uric acid (UA), and high-sensitive C-reactive protein
(CRP). The outcome measures were determined before
and after the intervention. We also measured the nutrient
intake and energy expenditure.
Table 1. Components of the test beverages
Intervention beverage Control beverage
Total catechin (mg) 400 100
Caffeine (mg) 105 80
Total energy (kJ) 0 0
Total protein (g) 0 0
Total fat (g) 0 0
Carbohydrate (g) 0 0
Sodium (mg) 46 53
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after the participants fasted overnight. Blood samples
were collected into a tube containing ethylenedia-
minetetraacetic acid (EDTA)-2Na and a tube containing
heparin. Serum and plasma samples were obtained by a
10-min centrifugation at 3,000 rpm within 30 min of
obtaining the sample. The samples were then transported
frozen to the SRL Laboratory in Hachioji, Tokyo, Japan,
and stored at below 208C until analysis. Serum
adiponectin level was determined by enzyme-linked
immunosorbent assay (ELISA; Otsuka Pharmaceutical,
Tokyo, Japan), serum TC level, CEH-CDH-UV method
(Sysmex Corporation, Hyogo, Japan), serum LDL-C
level, liquid selective detergent method (Sekisui Medical,
Tokyo, Japan), serum HDL-C level, accelerator selective
detergent method (Sekisui Medical, Tokyo, Japan), TG
level, enzymatic method without endogenous free glycerol
(Sekisui Medical, Tokyo, Japan), fasting plasma glucose
level, HK-G-6-PDH method (Shino-Test, Tokyo, Japan),
AST, ALT, and g-GTP levels, JSCC transferable method
(Kanto Chemical, Tokyo, Japan), UA level, enzymatic
method (Sekisui Medical), and the high-sensitive CRP
level was assayed by nephelometric immunoassay (Sie-
mens Healthcare Diagnostics, Tokyo, Japan).
BMI was calculated as body weight (kg) divided by
squared height (m
2). BP was measured using
a cuff placed on the upper arm of each participant in
the sitting position. Nutrition surveys were carried out
using a food frequency questionnaire (Excel Eiyokun)
(21). Energy expenditure was measured using Lifecorder
(Suzuken).
Statistical analysis
Comparisons between the two groups were performed by
Student’s t-test to assess the differences in the biochem-
ical and anthropometric parameters at baseline. Sex
ratio was compared by a Chi-squared test. Effects of
the intervention on serum adiponectin level and other
outcome measures were tested using a paired t-test in
each group before and after the intervention. Analysis
of covariance was used to investigate the significance of
the differences in the initial values as well as the net
changes after the intervention between the two groups.
We considered the following variables as potential con-
founders a priori: age at baseline in years (continuous
variable), sex, and baseline level of each variable.
All statistical analyses were performed using SAS version
9.1 (SAS Inc., Cary, NC, USA). Intention to treat
analysis was adopted. Approximate variance formulas
were used to calculate the 95% confidence intervals (CIs).
Differences were accepted as statistically significant at
pB0.05. In addition, stratified analyses according to
weight loss program (participation or non-participation)
were conducted.
Results
All the study participants completed the study; 95.9%
of the tea bottles were consumed in the high catechin
Randomization
High-catechin group Low-catechin group
(intervention group) (control group)
(N = 25)
(N = 25)
(N = 26)
(N = 26)
Lost to follow-up (N = 0) Lost to follow-up (N = 0)
Discontinued intervention (N = 0) Discontinued intervention (N = 0)
Analyzed participants Analyzed participants
9 subjects disagree to participate
60 subjects (assessed for eligibility)
51 subjects agree to participate
Fig. 1. Trial ﬂow chart.
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harmful effects were observed. At the end of the study,
we observed that more than half of the participants
were blinded.
Comparisons of baseline variables between the high-
and low catechin groups are shown in Table 2. No
significant difference in the baseline adiponectin level
was observed between the two groups. The proportion
of women was approximately 65% in both the groups.
With the exception of the baseline mean g-GTP level,
no other variable showed a significant difference between
the two groups.
Table 3 shows the changes in nutrient intake and
energy expenditure. There were significant reductions in
total energy intake and carbohydrate intake in any of
the groups. The intake of total fat, total dietary fiber,
sodium chloride, and tocopherol was significantly de-
creased in the low catechin group. However, the net
change between the groups was not significant.
Table 4 shows the changes in the serum adiponectin
level and CVD risk factors. After 9 weeks of catechin
consumption, the mean9SD changes from baseline in
the adiponectin level were 1.2992.77 mg/ml in the high
catechin group and 1.0091.87 mg/ml in the low catechin
group. We found no significant difference between the
high- and low catechin group with respect to changes
in the serum adiponectin level: 0.35 mg/ml (95% CI:
1.03, 1.74). There were significant decreases in the body
weight, BMI, and waist circumference in both the groups,
but the net change was not significant for any
of these variables. Furthermore, there were no significant
differences in the net change in other variables as well.
As for the net change in serum adiponectin, stratified
analyses according to weight loss program (participation
or non-participation) were conducted (Table 5). Among
weight loss program participants and weight loss pro-
gram non-participants, there were no significant differ-
ences in the net change: 0.15 mg/ml (95% CI: 1.54,
1.85) among weight loss program participants, and
1.49 mg/ml (95% CI: 0.46, 3.43) among weight loss
program non-participants.
Discussion
In this RCT, we tested a hypothesis that consumption of
catechin-enriched GTwould affect the serum adiponectin
level and CVD risk factors in apparently healthy subjects.
Table 2. Baseline characteristics of participants according to high-catechin group and low-catechin group
a
Variables High-catechin group (N25) Low-catechin group (N26) P-values
b
Serum adiponectin (mg/mL) 8.294.7 8.893.2 0.06
Age (years) 43.2914.8 48.2912.4 0.38
Women (%) 64.0 65.4 0.92
Body weight (kg) 66.4913.7 64.8913.7 0.97
Body mass index (kg/m
2) 24.694.3 24.594.2 0.92
Waist circumference (cm) 85.0912.7 85.7912.0 0.78
Systolic blood pressure (mmHg) 123915 123916 0.81
Diastolic blood pressure (mmHg) 75910 76910 0.71
Total cholesterol (mmol/L) 4.6690.82 4.9690.67 0.31
LDL cholesterol (mmol/L) 2.7090.68 2.9890.75 0.61
HDL cholesterol (mmol/L) 1.3790.36 1.4690.37 0.93
Triglyceride (mmol/L) 1.2091.15 1.3191.63 0.09
Fasting plasma glucose (mmol/L) 5.3090.68 5.4890.53 0.25
Aspartate aminotransferase (U/L) 21.997.2 19.996.0 0.37
Alanine aminotransferase (U/L) 19.2911.3 17.498.0 0.09
Gamma-glutamyl transpeptidase (U/L) 28.4928.0 31.9944.7 0.03
Uric acid (mmol/L) 308970 329976 0.70
High-sensitive C-reactive protein (ng/mL) 5119573 5219534 0.73
Energy intake (MJ/day) 7.8292.12 8.0191.77 0.39
Protein intake (g/day) 62.1920.4 69.5920.0 0.91
Fat intake (g/day) 55.8921.2 60.9918.6 0.52
Carbohydrate intake (g/day) 251963 252950 0.24
Energy expenditure (MJ/day) 8.7591.33 8.4991.60 0.56
aValues were expressed as mean9SD.
bP-values with chi-squared test for female ratio and for biochemical parameters, anthropometric parameters, nutrient intake, and energy expenditure,
with Student’s t-test.
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Variables Baseline Mean9SD After 9 weeks Mean9SD P-values
a Net change
b (95% CI) P-values
b
Energy intake (MJ/day)
High-catechin group 7.8292.12 7.0091.17 0.03 0.14 (0.83, 0.55) 0.68
Low-catechin group 8.0191.77 7.2291.63 0.009
Protein intake (g/day)
High-catechin group 62.1920.4 60.8916.5 0.75 0.91 (8.62, 6.80) 0.81
Low-catechin group 69.5920.0 66.5916.9 0.24
Fat intake (g/day)
High-catechin group 55.8921.2 50.8912.4 0.15 0.01 (6.12, 6.10) 0.99
Low-catechin group 60.9918.6 53.3914.9 0.006
Carbohydrate intake (g/day)
High-catechin group 251963 219934 0.01 7.82 (30.94, 15.29) 0.50
Low-catechin group 252950 227951 0.03
Total dietary fiber intake (g/day)
High-catechin group 12.194.5 11.794.9 0.64 0.33 (1.45, 2.10) 0.71
Low-catechin group 13.894.4 12.793.6 0.03
Sodium chloride intake (g/day)
High-catechin group 8.992.9 8.693.1 0.64 1.16 (0.52, 2.83) 0.17
Low-catechin group 10.894.3 8.793.9 0.01
Potassium intake (g/day)
High-catechin group 2.1690.78 2.0690.74 0.49 0.02 (0.30, 0.26) 0.89
Low-catechin group 2.4490.75 2.2990.61 0.07
Calcium intake (mg/day)
High-catechin group 5759230 5459213 0.48 12.29 (67.27, 91.86) 0.76
Low-catechin group 5819170 5569173 0.19
Magnesium intake (mg/day)
High-catechin group 236975 224979 0.53 0.98 (33.86, 31.90) 0.95
Low-catechin group 258978 244964 0.14
Iron intake (mg/day)
High-catechin group 6.7392.19 6.9092.32 0.74 0.44 (0.53, 1.41) 0.37
Low-catechin group 7.8092.56 7.1891.94 0.07
Zinc intake (mg/day)
High-catechin group 7.6292.23 7.2491.69 0.40 0.15 (0.93, 0.62) 0.69
Low-catechin group 8.2892.14 7.8191.74 0.09
Copper intake (mg/day)
High-catechin group 1.0290.29 0.9590.26 0.29 0.02 (0.14, 0.09) 0.68
Low-catechin group 1.1190.32 1.0490.25 0.10
Tocopherol intake (mg/day)
High-catechin group 6.9092.21 6.3691.64 0.18 0.08 (0.79, 0.62) 0.81
Low-catechin group 7.9392.53 7.0491.73 0.006
Vitamin K intake (mg/day)
High-catechin group 200981 2019105 0.94 8.99 (28.20, 46.19) 0.63
Low-catechin group 231989 218966 0.19
Vitamin C intake (mg/day)
High-catechin group 80945 82944 0.73 4.08 (9.05, 17.21) 0.54
Low-catechin group 100944 95938 0.22
Energy expenditure (MJ/day)
High-catechin group 8.7591.33 8.5191.27 0.06 0.09 (0.38, 0.19) 0.51
Low-catechin group 8.4991.50 8.3891.29 0.28
aPaired t test.
bThe change in high-catechin group minus the change in low-catechin group. The net differences were calculated by analysis of covariance. Adjusted for
age (in years), sex, and individual baseline variables.
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Variables Baseline Mean9SD After 9 weeks Mean9SD P-values
a Net change
b (95% CI) P-values
b
Serum adiponectin (mg/mL)
High-catechin group 8.294.7 9.595.7 0.03 0.35 (1.03, 1.74) 0.61
Low-catechin group 8.893.2 9.894.1 0.01
Body weight (kg)
High-catechin group 66.4913.7 64.9913.7 0.002 0.35 (1.44, 0.74) 0.52
Low-catechin group 64.8913.7 63.5913.1 0.001
Body mass index (kg/m
2)
High-catechin group 24.694.3 24.094.1 0.002 0.18 (0.58, 0.23) 0.39
Low-catechin group 24.594.2 24.193.9 0.003
Waist circumference (cm)
High-catechin group 85.0912.7 82.7912.2 0.007 0.73 (2.76, 1.29) 0.47
Low-catechin group 85.7912.0 83.9911.4 0.009
Systolic blood pressure (mmHg)
High-catechin group 123915 123919 0.96 0.14 (6.89, 6.61) 0.97
Low-catechin group 123916 123913 0.73
Diastolic blood pressure (mmHg)
High-catechin group 75910 74912 0.82 0.74 (4.34, 2.86) 0.68
Low-catechin group 76910 76910 0.92
Total cholesterol (mmol/L)
High-catechin group 4.6690.82 4.7590.77 0.27 0.10 (0.10, 0.31) 0.32
Low-catechin group 4.9690.67 4.9390.70 0.59
LDL cholesterol (mmol/L)
High-catechin group 2.7090.68 2.7690.73 0.41 0.07 (0.14, 0.28) 0.50
Low-catechin group 2.9890.75 2.9790.75 0.91
HDL cholesterol (mmol/L)
High-catechin group 1.3790.36 1.4290.37 0.13 0.04 (0.06, 0.15) 0.39
Low-catechin group 1.4690.37 1.4790.37 0.82
Triglyceride (mmol/L)
High-catechin group 1.2091.15 1.1491.06 0.40 0.25 (0.11, 0.62) 0.17
Low-catechin group 1.3191.63 0.9390.47 0.22
Fasting plasma glucose (mmol/L)
High-catechin group 5.3090.68 5.3490.75 0.65 0.12 (0.13, 0.38) 0.34
Low-catechin group 5.4890.53 5.3590.45 0.20
Aspartate aminotransferase (U/L)
High-catechin group 21.997.2 22.098.5 0.90 1.99 (1.06, 5.05) 0.20
Low-catechin group 19.996.0 19.295.7 0.38
Alanine aminotransferase (U/L)
High-catechin group 19.2911.3 20.299.8 0.52 1.93 (1.78, 5.63) 0.30
Low-catechin group 17.498.0 17.797.8 0.85
Gamma-glutamyl transpeptidase (U/L)
High-catechin group 28.4928.0 31.5932.0 0.07 4.61 (0.98, 10.19) 0.10
Low-catechin group 31.9944.7 29.4930.7 0.41
Uric acid (mmol/L)
High-catechin group 308970 315971 0.31 15.46 (4.16, 35.09) 0.12
Low-catechin group 329976 318978 0.16
High-sensitive C-reactive protein (ng/mL)
High-catechin group 5119573 5139496 0.99 85.92 (387.89, 216.06) 0.57
Low-catechin group 5219534 6279692 0.35
aPaired t test.
bThe change in high-catechin group minus the change in low-catechin group. The net differences were calculated by analysis of covariance. Adjusted for
age (in years), sex, and individual baseline variables.
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changes from baseline in the adiponectin level were
significantly increased in the both groups. However, we
found no significant difference between the high- and low
catechin group with respect to changes in the serum
adiponectin level: 0.35 mg/ml (95% CI: 1.03, 1.74).
The CVD risk factors, namely, body weight, BMI, and
waist circumference, were significantly decreased in both
the groups, but the net change was not significant for
any of these variables.
There are at least three reasons that the changes from
baseline in the adiponectin level were significantly
increased in both groups. First, more than half of the
study participants participated in a weight loss program.
Second, lifestyle of the study participants may have been
changed by this study. Third, catechin was contained not
only in high-concentration beverage (high catechin
group; 400 mg) but also in low-concentration beverage
(low catechin group; 100 mg). Therefore, if the low
concentration of the catechins might be enough to
increase the adiponectin levels, an increase would be
observed in the both groups.
In addition, we conducted stratified analyses according
to weight loss program (participation or non-participa-
tion) because the change in adiponectin levels in both the
groups may be related to the significant weight loss
program. We also found that there were no significant
differences in the net change among weight loss program
participants and non-participants. Because the net
change among weight loss program non-participants
was greater than that among weight loss program
participants, the change in adiponectin levels would be
less affected by the weight loss program.
To date, three RCTs have examined the association
between tea catechin consumption and adiponectin levels
in humans (1820). These RCTs recruited patients with
diabetes mellitus and obesity. Because these patients
might have had atherosclerosis before the study, the effect
of tea catechin consumption on serum adiponectin level
might not be well detected. Ryu et al. observed a change
in the adiponectin level after the consumption of 900 ml
of water containing 9 g of GT daily for 4 weeks in
patients with type 2 diabetes mellitus (18). After 4 weeks,
the mean9SD change in the adiponectin level from the
baseline value was 6.0393.71 mg/ml in intervention
group and 6.0193.16 mg/ml in control group, although
the net change between the groups was not significant.
Hsu et al. observed a significant increase in the adipo-
nectin level in obese women who consumed one capsule
containing 491 mg of total catechin daily (19). After
12 weeks, the mean9SD change in the adiponectin level
from the baseline value was 2.594.2 mg/ml in interven-
tion group and 2.095.4 mg/ml in control group, although
the net change was not significantly different. Nagao
et al. observed a significant increase in the adiponectin
level after the consumption of 582.8 mg of catechin daily
in patients with type 2 diabetes mellitus (20). After 12
weeks, the mean9SD change in the adiponectin level
from the baseline value was 1.3290.61 mg/ml in inter-
vention group and 0.3490.48 mg/ml in control group,
although the net change was not significantly different.
Thus, all the three RCTs showed that the increase in the
serum adiponectin level in the intervention group was
greater than that in the control group, although the net
change between the groups was not significant. Although
we recruited healthy participants who did not have a
history of diabetes mellitus, cancer, ischemic heart
disease, stroke, or renal disease, our findings were
consistent with those of the above reports.
Although we found no significant difference in the
net change in adiponectin level, several reasons should
be considered in the interpretation of our results. First,
Table 5. Change in serum adiponectin of participants according to high-catechin group and low-catechin group stratiﬁed by weight-loss
program
Variables Baseline Mean9SD After 9 weeks Mean 9SD P-values
a Net change
b (95% CI) P-values
b
Serum adiponectin (mg/mL)
Weight-loss program participants
High-catechin group (N15) 7.495.2 8.696.1 0.13 0.15 (1.54, 1.85) 0.86
Low-catechin group (N16) 8.193.1 9.093.8 0.10
Weight-loss program non-participants
High-catechin group (N10) 9.593.6 10.995.0 0.15 1.49 (0.46, 3.43) 0.12
Low-catechin group (N10) 9.993.1 11.194.3 0.06
aPaired t test.
bThe change in high-catechin group minus the change in low-catechin group. The net differences were calculated by analysis of covariance. Adjusted for
age (in years), sex, and baseline serum adiponectin.
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catechin dose between the high- and low catechin groups
and the intervention period. In the present study, the
difference in the catechin dose between the high- and
low catechin groups was only 300 mg/day and the
intervention period was 9 weeks. Hsu et al. adopted the
difference in the catechin dose of 491 mg/day and
intervention period of 12 weeks, but the net change in
adiponectin level was not significant (19). Also, Nagao
et al. adopted the difference in the catechin dose of 486.5
mg/day and intervention period of 12 weeks, but the net
change in adiponectin level was not significant (20).
Therefore, the difference in the catechin dose and the
intervention period could not explain our observation.
Second, because GT is consumed primarily in Japan
and China (22), habitual GT consumption may have the
potential to affect study results. Although we adopted the
washout period for 2 weeks, we did not find any apparent
association between catechin-enriched GT consumption
and adiponectin. Similarly, previous studies adopted the
washout period for 2 weeks (19) and 4 weeks (20), but
the net change in adiponectin level was not significant.
Ryu et al. also excluded subjects who had consumed GT
regularly for over a month, but the net change in
adiponectin level was not significant (18). Therefore, the
washout period could not explain our observation.
Third, the compounds such as caffeine found in GT
may have been responsible for the association between
GT consumption and CVD risk factors. A previous
observational study indicated the association between
consumption of caffeine-containing coffee and adiponec-
tin. No association between consumption of caffeine-
containing coffee and adiponectin was indicated in either
group (quartile 1: 0100 mg, quartile 2: 101237 mg,
quartile 3: 237378 mg, quartile 4: 379967 mg) among
non-diabetic subjects (23). Because the difference in the
caffeine dose between the high- and low catechin groups
was small (25 mg/day) in our study, caffeine could not
explain our observation.
Fourth, chocolate, red wine, apples, and berries are
known as good source of catechin (24, 25). Although we
asked participants not to drink any other catechin-
containing beverage, we had no information on the intake
of these food items during the 9 weeks. In addition, we
had no data on the levels of the major dietary catechins
(gallocatechin, epicatechin, epigallocatechin, etc.) and the
total blood antioxidant levels. However, these factors may
be divided equally between the high- and low catechin
groups by successful randomization. Also, a previous
study indicated that the half-lives of epigallocatechin-3-
gallate, epigallocatechin, and epicatechin once ingested
were 3.4, 1.7, and 2.0 h, respectively (26). Therefore, it is
difficult to interpret the results of all-night fasting plasma
levels of catechins, if measured.
Finally, our RCT design might yield a relatively small
number of participants, although we made a power
calculation regarding sample size. We found no signifi-
cant difference between the high- and low catechin groups
with respect to changes in the serum adiponectin level.
Our study had a similar sample size to previous RCTs,
and our results were consistent with results of previous
RCTs (19, 20). Therefore, a larger sample size may be
necessary to detect any effect of tea catechin consump-
tion on serum adiponectin level.
The present study also aimed to explore the changes
in CVD risk factors. We found no significant differences
in CVD risk factors between the high- and low catechin
groups. Many studies have assessed the relation between
GT consumption and CVD risk factors. In previous
studies, the GT consumption showed statistically signifi-
cant reductions in body weight, BMI, and waist circum-
ference (2729). Our study showed that decrease in the
anthropometric parameters in the high catechin group
was greater than that in the low catechin group, although
the net change between groups was not significant. The
previous studies that suggested statistically significant
changes had a larger sample size (28, 29). Therefore,
a larger sample size may be necessary to detect the effect
of tea catechin consumption on the anthropometric
parameters.
The effect of GT consumption on BP has been
investigated in meta-analysis of previous studies. These
data suggested that GT consumption did not show
significant effects on systolic and diastolic BP (30). Our
results on BP were consistent with the previous studies.
Among previous studies that have examined the
association between GT and blood cholesterol (TC,
LDL-C, and HDL-C), GT consumption significantly
lowered the TC and LDL-C level, but no effect on
HDL-C was observed (20, 28, 30, 31). Our results on
HDL-C were consistent with previous studies, but the
inconsistent findings on the effect of GT consumption
on TC and LDL-C were observed. There are several
possible reasons for the discrepancy between our study
and previous studies on TC and LDL-C. First, the
subjects of the previous studies were not a healthy
population (20). Therefore, one of the reasons for
discrepancy might be explained by the difference in the
study subjects. Second, the sample size in the previous
studies was large (28). Therefore, another reason for
discrepancy might be explained by sample size.
Conclusions
This RCT showed that increase in serum adiponectin
level in the high catechin group was greater than that
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between groups was not significant. Also, no significant
difference was observed between the high- and low
catechin groups with respect to changes in any CVD
risk factors.
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